NEW YORK (GenomeWeb News) – BiOasis Technologies today said that it will receive cash proceeds of C$1.7 million (US$1.4 million) from the exercise of warrants that expired on March 31.

The Vancouver, BC-based developer of therapeutics and molecular diagnostics for neurological diseases said that a result of the warrants being exercised it now has cash and cash equivalents of C$2.4 million. The additional funds will enable the firm to fund a final trial of the p97 biomarker as a diagnostic for Alzheimer's disease.